Efruxifermin
Phase 3Protein / enzyme
Akero TherapeuticsEfruxifermin is a protein / enzyme that works as a FGF21 Fc Fusion.[2] It is being investigated across 2 indications, with its most advanced program in Phase 3.[1]
Efruxifermin is one of 33 fusion protein programs targeting Non-Alcoholic Steatohepatitis. It is currently in Phase 3.
2
Indications
4
Total Trials
3
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Non-Alcoholic Steatohepatitis
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Rifadin
SanofiApproved
Mounjaro
Eli LillyApproved
Cytotec
PfizerApproved
Aldactone
PfizerApproved
Estrace
Novo NordiskApproved
Trental
VValidus Pharmaceuticals
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Ozempic
Novo NordiskPhase 3
Tricor
JJagotec
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatitis1 trial
Alcoholic Fatty Liver Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Efruxifermin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- FGF21 Fc Fusion[2]
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company